The Fast Track designation facilitates the development of new therapies that fill an unmet medical need for serious conditions in an effort to expedite the availability of new The post FDA grants fast track designation to empagliflozin to treat chronic heart failure appeared first on Pharmaceutical Business review.
12:01
The approval allows the drug firms to use Dupixent with other medicines for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not The post Regeneron, Sanofi get FDA nod for Dupixent to treat chronic rhinosinusitis with nasal polyps appeared first on Pharmaceutical Business review.
11:03
TILT-123 has been engineered to selectively replicate only in cancer cells that produce the TNFa and IL-2 immunostimulatory cytokines locally at the tumour as shown in various in The post TILT Biotherapeutics to evaluate TILT-123, avelumab combo in solid tumours appeared first on Pharmaceutical Business review.
11:03
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου